Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evencaleucel - XNK Therapeutics

Next Previous
X
Search
Drug Profile

Evencaleucel - XNK Therapeutics

Alternative Names: ACP-001- XNK Therapeutics

Latest Information Update: 23 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator XNK Therapeutics
  • Developer Karolinska Institute; Sanofi; XNK Therapeutics
  • Class Antineoplastics; Immunotherapies; Natural killer cell therapies
  • Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Multiple myeloma

Most Recent Events

  • 15 Jan 2024 XNK Therapeutics receives scientific recommendation from the Committee for Advanced Therapies (CAT) for evencaleucel as an Advanced Therapy Medicinal Product
  • 10 Jun 2022 Efficacy and adverse events data from a phase I/II trial in Multiple myeloma released by XNK Therapeutics
  • 02 Jun 2021 Phase-II clinical trials in Multiple myeloma (First-line therapy, Combination therapy) in Sweden (IV) in June 2021 (EudraCT2020-000994-26) (NCT04558931)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top